You are right, meningo is sepsis. Sepsis, in a certain sense, is like cancer. A drug that works in lymphoma does not necessarily work in colon cancer. Accordingly, I don't speculate on off-label use. Moreover, insurance companies will also need evidence that the drug works in, e.g., multiresistant Staphylococcus sepsis, to cover expenses.
I speculate, however, that approval will approximately double the share price, at least for a while. It would be nice to catch it. When do we expect NDA review and advisory panel meeting? |
